January 29, 2021

meet the PI on the UK arm of the Novavax vaccine trial

Last night, Novavax announced the results of Phase III trials on its protein-based COVID-19 vaccine candidate showing 89.3% efficacy. The Principal Investigator on the trial is Prof Paul Heath from St George’s, University of London. The SMC  invited Paul to brief science journalists about his trial, talk them through the results and answer their questions.

Speakers included:

Prof Paul Heath, Principal Investigator of the UK arm of the Novavax vaccine trial, and Professor of Paediatric Infectious Diseases and Director of the Vaccine Institute, St George’s, University of London

SMC Rapid Reaction on Novavax announcing Phase III results for their COVID-19 vaccine candidate.